ELI LILLY & Co (LLY)
About ELI LILLY & Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $65.2B
- Net income
- $20.6B
- Total assets
- $112.5B
- Market cap
- $1.1T
- Gross margin
- 83.0%
- Operating margin
- 39.5%
- Net margin
- 31.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $65.2B
- Cost of revenue
- $11.1B
- Gross profit
- $54.1B
- Operating expenses
- $28.4B
- Operating income
- $25.7B
- Income tax
- $5.1B
- Net income
- $20.6B
- EPS (basic)
- $23.00
- EPS (diluted)
- $22.95
Balance sheet
- Total assets
- $112.5B
- Current assets
- $55.6B
- Total liabilities
- $85.9B
- Current liabilities
- $35.2B
- Shareholders’ equity
- $26.5B
Cash flow
- Operating cash flow
- $16.8B
- Investing cash flow
- -$11.0B
- Financing cash flow
- -$2.2B
- Net cash flow
- $4.0B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.1T
- P/E ratio
- 51.2
- EPS (diluted)
- $22.95
- Dividend yield
- 0.59%
- Shares outstanding
- 906.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 9, 1970
ELI LILLY & Co (LLY) Stock Price
- Profitable — net income of $20.6B in FY2025.
- Revenue grew 130% from FY2021 to FY2025.
- Gross margin of 83.0%, net margin 31.7%.
- Trading 8% below its 52-week high.
- Pays a dividend yielding about 0.59% annually.
- Valued at a price-to-earnings (P/E) ratio of 51.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ELI LILLY & Co.
Write a review
News about ELI LILLY & Co
News & sentiment via Polygon.io
ELI LILLY & Co: frequently asked questions
Is ELI LILLY & Co an American company?
Yes — ELI LILLY & Co is an American company headquartered in Indianapolis, Indiana. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is ELI LILLY & Co headquartered?
ELI LILLY & Co is headquartered in Indianapolis, Indiana, United States.
Is ELI LILLY & Co publicly traded?
Yes — ELI LILLY & Co is a publicly traded company. Its stock trades under the ticker symbol LLY on the NYSE.
What does ELI LILLY & Co do?
ELI LILLY & Co is an American Pharmaceuticals company in the Health & Beauty sector.
When was ELI LILLY & Co founded?
ELI LILLY & Co was founded in 1875.
